home / stock / otlkw / otlkw articles

OTLKW Articles, Outlook Therapeutics Inc. Series A Warrant

Stock Information
Company Name: Outlook Therapeutics Inc. Series A Warrant
Stock Symbol: OTLKW
Market: NASDAQ
Website: outlooktherapeutics.com
Menu
OTLKW OTLKW Quote OTLKW Short OTLKW News OTLKW Articles OTLKW Message Board
Get OTLKW Alerts

News, Short Squeeze, Breakout and More Instantly...
Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference | Benzinga

Live video webcast on Tuesday, June 18th at 12:00 PM ET ISELIN, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTL...
Outlook Therapeutics® to Present at the Retina World Congress 2024 | Benzinga

ISELIN, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to achieve the firs...

Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase | Benzinga

ISELIN, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to achieve the fi...

Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million | Benzinga

ISELIN, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to achieve the fi...
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million | Benzinga

ISELIN, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to achieve the fi...

Outlook Therapeutics® Announces Strategic Organizational Realignment | Benzinga

Realignment focused on supporting ONS-5010 U.S. and EU regulatory and commercial priorities Continued progress toward commencement of additional ...

Outlook Therapeutics® Adds Global Commercial Expertise with Appointment of Jedd Comiskey as Senior VP - Head of Europe | Benzinga

ISELIN, N.J., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to achieve FDA app...
Outlook Therapeutics® to Present at Guggenheim's 5th Annual Inflammation, Neurology & Immunology (INI) Conference | Benzinga

ISELIN, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to achieve FDA app...

Outlook Therapeutics® to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference | Benzinga

ISELIN, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to achieve FDA ap...

Outlook Therapeutics® to Present at the H.C. Wainwright 25th Annual Global Investment Conference | Benzinga

ISELIN, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to achieve FDA ap...
Next 10